Evidence map›Paper›PMID 25930994›Full record

ArticleNeurogastroenterology and motility2015

Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

G Cipriani, S J Gibbons, S A Saravanaperumal, J Malysz, L Sha, J H Szurszewski, D R Linden, S Evangelista, M S Faussone-Pellegrini, M G Vannucchi and 1 more

Open access · greenAbstract read
In one paragraph

Article in Neurogastroenterology and motility, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

G CiprianiEnteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
S J GibbonsEnteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
S A SaravanaperumalEnteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
J MalyszEnteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
L ShaEnteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
J H SzurszewskiEnteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
D R LindenEnteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
S EvangelistaPreclinical Development, Menarini Ricerche SpA, Florence, Italy.
M S Faussone-PellegriniDept. Experimental and Clinical Medicine, Histology and Embryology Research Unit, Florence, Italy.
M G VannucchiDept. Experimental and Clinical Medicine, Histology and Embryology Research Unit, Florence, Italy.
G FarrugiaEnteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
Mayo Clinic in Arizona · USDepartment of Embryology · USMenarini Group (Italy) · IT

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Nicholas F. LaRusso · 2009 to 2026
$22.2M
CALCIUM DYNAMICS IN INTERSTITIAL CELLS OF CAJALR01DK057061 · NIDDK · MAYO CLINIC ROCHESTER · PI GIANRICO FARRUGIA, Tamas Ordog · 2000 to 2026
$8.2M
NIDDK NIH HHS DK57061NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK057061
6 · The paper itself

Abstract

backgroundOtilonium bromide (OB) is used as a spasmolytic drug in the treatment of the functional bowel disorder irritable bowel syndrome. Although its acute effects on colonic relaxation are well-characterized, little is known about the effects of chronic administration of OB on enteric neurons, neuromuscular transmission, and interstitial cells of Cajal (ICC), key regulators of the gut function.

methodsAdult Sprague-Dawley rats were treated with OB in drinking water at a dose of 2 mg/kg for 30 days. The colons of OB-treated and age-matched control rats were studied by confocal immunohistochemistry to detect immunoreactivity (IR) in myenteric plexus neurons for nitrergic and tachykininergic markers, and also by microelectrode electrophysiology. KEY

resultsUsing immunohistochemistry, chronic OB administration did not change total neuron number, assessed by anti-Hu IR, but resulted in a significant increase in NK1 receptor positive neurons, a decrease in neuronal nitric oxide synthase expressing neurons, and a reduction in volume of substance P in nerve fibers in the myenteric plexus. Chronic OB administration potentiated inhibitory and excitatory junction potentials evoked by repetitive electrical field stimulation. The various types of colonic ICC, detected by Kit IR, were not altered nor were slow waves or smooth muscle membrane potential. CONCLUSIONS & INFERENCES: Chronic treatment with OB caused significant changes in the nitrergic and tachykinergic components of the myenteric plexus and in both inhibitory and excitatory neurotransmission in the rat colon.

Indexed as

AnimalsColonMaleMyenteric PlexusNitric OxideNitric Oxide Synthase Type IQuaternary Ammonium CompoundsRatsRats, Sprague-DawleyReceptors, Neurokinin-1Signal TransductionTachykininsNitric OxideNitric Oxide Synthase Type INos1 protein, ratoctyloniumQuaternary Ammonium CompoundsReceptors, Neurokinin-1Tachykininsantispasmodicconfocal microscopyenteric nervous systemexcitabilityinterstitial cells of Cajaljunction potentialmyenteric plexusnerve-evoked activityslow wave

Identifiers

PMID25930994
PMCPMC4478139
OpenAlexW2017576585

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.